From: Genomically personalized therapy in head and neck cancer
Trials | Trial phase | Drug 1 | Drug 2 | Pathway 1 | Pathway 2 | Setting | Status |
---|---|---|---|---|---|---|---|
NCT01716416 | 1 | Pazopanib | Cetuximab | Angiogenesis | EGFR | Recurrent, metastatic | Recruiting |
NCT02499120 | 2 | Palbociclib | Cetuximab | Cell cycle | EGFR | Plcebo controlled randomized phase II, recurrent, metastatic | Recruiting |
NCT02101034 | 1,2 | Palbociclib | Cetuximab | Cell cycle | EGFR | Recurrent, metastatic | Recruiting |
NCT01711541 | 1, 2 | Veliparib | Chemotherapy | DNA repair | EGFR | Recurrent, metastatic | Recruiting |
NCT02538627 | 1 | MM-151 | MM-121 | EGFR | ERBB | Recurrent, metastatic | Recruiting |
NCT02501096 | 1, 2 | Pembrolizumab | Lenvatinib | Immune | Angiogenesis | Recurrent, metastatic | Recruiting |
NCT02454179 | 2 | Pembrolizumab | ACP-196 | Immune | Bruton Tyrosine Kinase | Recurrent, metastatic | Recruiting |
NCT02646748 | 1 | Pembrolizumab | INCB039110/INCB050465 | Immune | JAK/PI3K | Recurrent, metastatic | Recruiting |
NCT01468896 | 1, 2 | Recombinant interleukin-2 | Cetuximab | Immune | EGFR | Recurrent, metastatic | Active, not recruiting |
NCT02507154 | 1, 2 | NK cells | Cetuximab | Immune | EGFR | Recurrent, metastatic | Recruiting |
NCT02643550 | 1, 2 | Monalizumab | Cetuximab | Immune | EGFR | Recurrent, metastatic | Recruiting |
NCT02110082 | 1 | Urelumab | Cetuximab | Immune | EGFR | Recurrent, metastatic | Active, not recruiting |
NCT02124850 | 1 | Motolimod/Nivolumab | Cetuximab | Immune | EGFR | Stage II-IVA, neoadjuvant | Recruiting |
NCT02586987 | 1 | MEDI4736 | Selumetinib | Immune | MEK | Recurrent, metastatic | Recruiting |
NCT01871311 | 1 | Nilotinib | Cetuximab | Kit | EGFR | Recurrent, metastatic | Recruiting |
NCT02277197 | 1 | Ficlatuzumab | Cetuximab | MET | EGFR | Recurrent, metastatic | Recruiting |
NCT01332266 | 1, 2 | E7050 | Cetuximab | MET | EGFR | Recurrent, metastatic | Recruiting |
NCT02205398 | 1 | INC280 | Cetuximab | MET | EGFR | Recurrent, metastatic | Recruiting |
NCT01285037 | 1 | LY2801653 | Cetuximab | MET | EGFR | Recurrent, metastatic | Recruiting |
NCT01602315 | 1b, 2 | BYL719 | Cetuximab | PI3K | EGFR | Recurrent, metastatic | Active, not recruiting |
NCT01488318 | 2 | Dasatinib | Cetuximab | Scr | EGFR | Recurrent, metastatic | Recruiting |